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Clinical PerspectiveWhat Is New?The exact mechanism explaining the benefits of treatment with ferric carboxymaltose in patients with heart failure remains not fully explained.This study shows that treatment with ferric carboxymaltose resulted in significant short‐term changes in cardiac magnetic resonance sequences that are consistent with myocardial iron repletion.What Are the Clinical Implications?This study opens a new line of research about the utility of cardiac magnetic resonance for noninvasive quantification of myocardial iron status, including not only iron overload, but also iron deficiency and response to treatment (myocardial iron repletion).

Introduction {#jah34791-sec-0009}
============

Iron deficiency (ID) is common in patients with heart failure (HF).[1](#jah34791-bib-0001){ref-type="ref"} It is associated with reduced functional capacity, quality of life, and increased risk of clinical events.[1](#jah34791-bib-0001){ref-type="ref"}, [2](#jah34791-bib-0002){ref-type="ref"}, [3](#jah34791-bib-0003){ref-type="ref"}, [4](#jah34791-bib-0004){ref-type="ref"} In patients with HF and ID (HF‐ID), with or without anemia, iron treatment with intravenous ferric carboxymaltose (FCM) has consistently been shown to improve symptoms, functional capacity, and quality of life with an acceptable safety profile.[5](#jah34791-bib-0005){ref-type="ref"}, [6](#jah34791-bib-0006){ref-type="ref"}, [7](#jah34791-bib-0007){ref-type="ref"}, [8](#jah34791-bib-0008){ref-type="ref"} The mechanisms whereby exogenous iron repletion leads to clinical improvement in HF‐ID are not completely understood.

Experimental studies have shown that iron depletion impairs mitochondrial function and adenosine triphosphate (ATP) synthesis affecting systolic and diastolic properties of cardiomyocytes, and that all these deleterious effects are reversed with iron treatment.[9](#jah34791-bib-0009){ref-type="ref"}, [10](#jah34791-bib-0010){ref-type="ref"}, [11](#jah34791-bib-0011){ref-type="ref"}, [12](#jah34791-bib-0012){ref-type="ref"} In humans, some studies have also shown that myocardial iron content is decreased in patients with advanced HF[13](#jah34791-bib-0013){ref-type="ref"} and this is associated with abnormal myocardial mitochondrial function.[14](#jah34791-bib-0014){ref-type="ref"} However, in the clinical setting, the myocardial effects of intravenous iron repletion in patients with HF‐ID are largely unknown.

A cardiac magnetic resonance (CMR) sequence, T2\*, has been shown to provide a noninvasive estimation of myocardial iron overload[15](#jah34791-bib-0015){ref-type="ref"}, [16](#jah34791-bib-0016){ref-type="ref"} and myocardial iron depletion.[17](#jah34791-bib-0017){ref-type="ref"} Native T1 mapping has also emerged as a potential alternative tool for the assessment of myocardial iron content.[18](#jah34791-bib-0018){ref-type="ref"} In a recently published proof‐of‐concept pilot study of 8 patients with HF‐ID, our group reported an association between intravenous FCM administration and myocardial iron repletion estimated by T2\* CMR.[19](#jah34791-bib-0019){ref-type="ref"} To further confirm these findings, the present study is a prospective multicenter, double‐blind, randomized clinical trial of noninvasive estimation of changes in myocardial iron after administration of FCM or placebo in patients with HF‐ID using CMR T2\* and T1 mapping sequences.

Methods {#jah34791-sec-0010}
=======

Overall Study Design {#jah34791-sec-0011}
--------------------

The data that support the findings of this study are available from the corresponding author upon reasonable request. This investigator‐initiated, multicenter, double‐blind, randomized clinical trial was designed to evaluate the effect of intravenous FCM versus placebo on myocardial iron repletion estimated by T2\* and T1 mapping CMR sequences in patients with HF‐ID. The trial was conducted in 5 academic centers in Spain.[20](#jah34791-bib-0020){ref-type="ref"} The patients provided signed informed consent before being randomized 1:1 to receive either FCM or placebo. Intramyocardial iron was evaluated at 3 time points: before treatment, and 7 and 30 days after treatment. At 30 days, patients assigned to placebo received intravenous FCM if ID persisted. The study design was already published.[20](#jah34791-bib-0020){ref-type="ref"}

The investigation conforms to the principles outlined in the Declaration of Helsinki and Good Clinical Practice of the International Conference on Harmonization. The study protocol was approved by Agencia Española del Medicamento y Productos sanitarios (AEMPS) and by Comité Ético de Investigación Clínica (CEIC) del Hospital Clínico Universitario de Valencia. CMR studies were performed and analyzed by a core lab at ERESA (Valencia). Laboratory parameters were analyzed in local laboratories. This study is registered at <http://clinicaltrials.gov> (NCT03398681).

Study Population {#jah34791-sec-0012}
----------------

The study population included patients with stable chronic HF (New York Heart Association \[NYHA\] II--III), left ventricular ejection fraction (LVEF) \<50%, and ID (serum ferritin \<100 μg/L \[absolute ID\] or 100--299 μg/L with transferrin saturation \[TSAT\] \<20% \[functional ID\]), and hemoglobin \<15 g/dL.[21](#jah34791-bib-0021){ref-type="ref"} The inclusion and exclusion criteria were published previously[20](#jah34791-bib-0020){ref-type="ref"} and are reported in detail in Table [S1](#jah34791-sup-0001){ref-type="supplementary-material"}.

Study Procedures {#jah34791-sec-0013}
----------------

### Screening and eligibility assessment (visit 0) {#jah34791-sec-0014}

In this visit, after reviewing the inclusion/exclusion criteria, the patients signed and dated the informed consent form. The following information was recorded: (1) clinical and demographic variables, including a complete medical history, vital signs, and a complete physical examination; (2) ECG; (3) functional capacity parameters, including NYHA functional class and 6‐minute walking test (6MWT); (4) quality of life parameters, including Kansas City Cardiomyopathy Questionnaire (KCCQ); (5) laboratory data, including hematology parameters, serum electrolytes, parameters evaluating iron status (ferritin and TSAT), creatinine, urea, estimated glomerular filtration rate, and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide); (6) 2‐dimensional echocardiography; and (7) CMR parameters.

### 24‐hour visit {#jah34791-sec-0015}

At this visit, after clinical evaluation, the patients were randomized to receive FCM or placebo. In addition, vital signs, complete physical examination, and functional class evaluation (NYHA) were noted.

### 7‐ and 30‐day visits {#jah34791-sec-0016}

At these visits, the same explorations/variables were recorded as at visit 0, except the ECG and echocardiography, which were performed only at the 30‐day visit. During the study period, all concomitant medications and clinical adverse events (death from all causes or hospitalization for acute HF) were recorded. Optional visits were permitted at the discretion of the physician in charge, at which the same information was recorded as in the preplanned visits.

### Cardiac magnetic resonance {#jah34791-sec-0017}

CMR studies were performed by 2 experienced operators on a 1.5‐Tesla MR scanner (Essenza y Avanto, Siemens, Erlangen, Germany) using the spine and phased array 6‐channel surface coils. No contrast media were used. All images were obtained with electrocardiographic gating and breath‐holding. Cine images were acquired at rest in short‐axis views every 1 cm with steady‐state free precession imaging sequences (time resolution: 37 ms; voxel size: 1.7×1.7×7 mm). The LVEF was calculated by semiautomatic planimetry of endocardial and epicardial borders in short‐axis view cine images. Left ventricle diameters and volumes were also determined.

For T2\* analysis, a region of interest was chosen in the mid‐left ventricular septum. The mean signal intensities of the regions of interest were measured in the series of increasing echo time images to give an exponential decay curve. The monoexponential decay model and nonlinear curve fitting algorithm were used to fit the curve to obtain the T2\* measurement. T1 mapping was performed using Modified Look‐Locker Inversion Recovery sequences with motion correction (voxel size: 1.5×1.5×7 mm) in 3 short axes (basal, medial, and apical). After T1 maps were generated, a region of interest was chosen in the mid‐left ventricular septum in the 3 short axes and the average T1 values were calculated. The same protocol was repeated at 7 and 30 days. The technical specifications of the CMR sequences were described elsewhere.[20](#jah34791-bib-0020){ref-type="ref"} CMR operators were also blinded to treatment allocation.

Trial Intervention {#jah34791-sec-0018}
------------------

Eligible patients were randomized to receive FCM or placebo. All patients received the assigned treatment with no place for crossover.

### Intravenous FCM or placebo {#jah34791-sec-0019}

FCM solution (Ferinject^®^ \[FCM\], Vifor Pharma, Glattbrugg, Switzerland) was given as a 20‐mL perfusion (equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% wt/vol NaCl) administered over at least 15 minutes after completion of all baseline study‐related assessments. Because FCM is a dark‐brown solution that is easily distinguishable from the saline placebo, study personnel responsible for the preparation and administration of the study drug were aware of the group assignments and, therefore, not involved in any study assessments.

In the placebo group, normal saline (0.9% weight/volume NaCl) was administered as per the instructions for active therapy. To ensure that patients were unaware of the study drug, the materials used in drug administration were covered with aluminum foil and the injection site shielded from the patient view.

### Concomitant drugs {#jah34791-sec-0020}

Indications for other HF‐related drugs in both treatment groups were handled according to the current recommendations for clinical practice and included the administration of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, sacubitril/valsartan, β‐blockers, mineralocorticoid receptor antagonists, digoxin, ivabradine, diuretics, and nitrate agents. Per study protocol, changes in HF therapy during the study period were discouraged.

End Points {#jah34791-sec-0021}
----------

### Primary end point {#jah34791-sec-0022}

The main end point was to noninvasively estimate changes in myocardial iron content as measured by T2\* and T1 mapping CMR sequences 7 and 30 days after FCM or placebo administration.

### Secondary end points {#jah34791-sec-0023}

The secondary end point was to correlate posttreatment changes in myocardial iron content (T2\* and T1 mapping) with concomitant changes in surrogate markers of disease severity (LVEF, functional capacity \[6MWT and NYHA class\], quality of life \[KCCQ\], NT‐proBNP, and blood markers related to iron biology \[ferritin and TSAT\]).

### Safety end points {#jah34791-sec-0024}

A strict policy was implemented regarding close adverse event surveillance to ensure early detection and appropriate management. Based on previous studies,[7](#jah34791-bib-0007){ref-type="ref"}, [8](#jah34791-bib-0008){ref-type="ref"} the surveillance specifically focused on (1) general disorders and administration site conditions, (2) skin and subcutaneous tissue disorders, (3) nervous system disorders, (4) gastrointestinal disorders, (5) vascular disorders, (6) ear and labyrinth disorders, (7) injury, poisoning, and procedural complications, and (8) cardiac disorders.

### Subgroup analyses {#jah34791-sec-0025}

We also included as part of the analysis the effect of treatment on changes in T2\* and T1 among age (≤75 years versus \>75 years), ischemic heart disease (0/1), and anemia (0/1) categories.

Follow‐Up {#jah34791-sec-0026}
---------

No patients were lost to follow‐up. T2\* and T1‐mapping values could not be accurately obtained in 3 and 2 patients, respectively. Reasons for unavailability included rejection for repeating the CMR test (n=1 patient) and technical issues in image acquisition (n=2 patients). In these cases, T2\* and T1 mapping values were imputed.

Statistical Analysis {#jah34791-sec-0027}
--------------------

All statistical comparisons were made under an intention‐to‐treat principle. Continuous variables were presented as median with interquartile range. Discrete data were expressed as frequency and percentages. The χ^2^ test or Wilcoxon rank‐sum were used as appropriate to compare baseline characteristics among the 2 treatment groups.

The statistical comparisons for the primary efficacy end point tested the null hypothesis of no differences in changes in myocardial iron content as estimated by T2\* and T1 mapping CMR in patients treated with intravenous FCM or placebo at 30 days. The alternative hypothesis stated differences in either direction. Because of the availability of 2‐time points, the 7‐day evaluation was considered a co‐primary end point.

A linear mixed regression model was used for the analysis of the primary end point. All analyses included adjustments for hospital center (as a cluster variable), the interaction term treatment×visit (7 and 30‐day), and the baseline (pretreatment) value of the regressed outcome. The inclusion of other covariates was based on clinical judgment or randomization inequalities at baseline. To limit the potential for increasing type I error rate, we focused strictly on between‐group (FMC versus placebo) comparison at 30 and 7 days, respectively.

A similar approach was used for the subgroup analyses after stratifying for the prespecified variables (age \[≤75 years versus \>75 years\], ischemic heart disease \[0/1\], and anemia \[0/1\]). Such linear mixed regression model included a 3‐level interaction (FCM treatment×visit×subgroup variable).

For analysis of the correlations between changes in either T2\* or T1 mapping and changes in LVEF, 6MWT, NYHA class, KCCQ, NT‐proBNP, ferritin, and TSAT, we used linear regression analysis. For this analysis, the stratification at 7 and 30 days was ignored under the assumption that these correlations may remain the same throughout follow‐up. These correlation models included the interaction between the treatment and the delta of the parameter evaluated. The normality of residuals was checked.

As a prespecified analysis, no adjustment for multiple comparisons was made in any of the analyses. Results from linear mixed regression model and linear regression analysis are presented as least‐square means with 95% CIs and *P* values.

Missing values in T2\* and T1 mapping were imputed using a reference‐based sensitivity analysis via multiple imputation for longitudinal trials with protocol deviation.[22](#jah34791-bib-0022){ref-type="ref"} A 2‐sided *P* value of 0.05 was considered significant for all analyses. All analyses were performed using Stata 15.1 (Stata Statistical Software, College Station, TX). The multiple imputation procedure was implemented with a special module within Stata called "mimix."

Results {#jah34791-sec-0028}
=======

Trial Population {#jah34791-sec-0029}
----------------

From May 2017 to June 2018, a total of 55 patients were preselected for participation in this trial. Fifty‐three patients were finally randomized to receive FCM (n=27) or placebo (n=26) (Figure [1](#jah34791-fig-0001){ref-type="fig"}).

![Flow chart. FCM indicates ferric carboxymaltose; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide.](JAH3-9-e014254-g001){#jah34791-fig-0001}

The median age of the study population was 73 (interquartile range 65--78) years, 75.5% were men, 52% had type 2 diabetes mellitus, 43.4% had prior ischemic heart disease, 60.4% had a prior admission for acute heart failure in the last 12 months, and most (94.3%) were in NYHA functional class II. The median (interquartile range) CMR‐LVEF, NT‐proBNP, and estimated glomerular filtration rate were 39% (33--45), 1690 pg/mL (1010--2828), and 60 (49.3--72.9) mL/min per 1.73 m^2^, respectively. All patients had ID at baseline, with 37 (69.8%) and 16 (30.2%) patients exhibiting absolute and functional ID, respectively. The median (interquartile range) values of ferritin and TSAT were 63 (33--114) μg/L and 15.7% (11--19.2%), respectively. Anemia (WHO criteria) was present in 16 (30.2%) patients. Baseline ferritin and TSAT did not correlate with T2\* (Spearman *r*=−0.08, *P*=0.552 and Spearman *r*=−0.199, *P*=0.153, respectively) or T1 mapping (Spearman *r*=−0.02, *P*=0.903 and Spearman *r*=−0.173, *P*=0.216, respectively). The baseline characteristics of patients in the 2 treatment groups are given in Table [1](#jah34791-tbl-0001){ref-type="table"}. No significant differences were found between the treatment groups. Raw data (CMR parameters \[T2\*, T1‐mapping, and LVEF\], KCCQ, and 6MWT at different visits \[baseline, 7 and 30‐day\]) across treatment arms are presented in Table [S2](#jah34791-sup-0001){ref-type="supplementary-material"}.

###### 

Baseline Characteristics

  Variables                                         Placebo (n=26)         Intravenous Iron (n=27)   *P* Value
  ------------------------------------------------- ---------------------- ------------------------- -----------
  Demographics and medical history                                                                   
  Age, y                                            71 (67, 79)            73.5 (64, 77)             0.957
  Male, n (%)                                       19 (73.1)              21 (77.8)                 0.691
  Hypertension, n (%)                               19 (73.1)              22 (81.5)                 0.465
  Dyslipidemia, n (%)                               16 (61.5)              18 (66.7)                 0.697
  Diabetes mellitus, n (%)                          14 (53.8)              15 (55.6)                 0.901
  Former smoker, n (%)                              16 (61.5)              15 (55.6)                 0.659
  Coronary artery disease, n (%)                    10 (38.5)              13 (48.1)                 0.477
  Prior admission for AHF in the last year, n (%)   16 (61.5)              16 (59.3)                 0.865
  COPD, n (%)                                       6 (23.1)               7 (25.9)                  0.810
  CKD, n (%)                                        7 (26.9)               8 (29.6)                  0.827
  Stroke, n (%)                                     6 (23.1)               2 (7.4)                   0.111
  Peripheral artery disease, n (%)                  4 (15.4)               4 (14.8)                  0.954
  NYHA functional class, n (%)                                                                       0.080
  II                                                26 (100)               24 (88.9)                 
  III                                               0                      3 (11.1)                  
  Vital signs                                                                                        
  Heart rate, bpm                                   68 (64, 77)            73 (68, 82)               0.262
  SBP, mm Hg                                        125 (113, 146)         117 (109, 132)            0.142
  ECG                                                                                                
  Atrial fibrillation, n (%)                        14 (53.8)              10 (37.0)                 0.219
  LBBB, n (%)                                       6 (23.1)               6 (22.2)                  0.941
  LVEF, %                                           37 (32, 43)            40 (33.5, 45)             0.643
  CMR parameters                                                                                     
  LVEDVI, mL/m^2^                                   122.1 (101.5, 137.9)   107 (80.1, 143.9)         0.109
  LVESVI, mL/m^2^                                   72.5 (55.1, 87.6)      63.5 (40.6, 84)           0.096
  LVEDDI, mm/m^2^                                   30.8 (28, 33.5)        30.9 (26.9, 31.9)         0.493
  LVESDI, mm/m^2^                                   23.1 (21.1, 26.9)      23.7 (23.0, 26.8)         0.648
  LVEF, %                                           37 (31, 45)            43 (36, 48)               0.128
  T2\*, ms                                          37 (31, 42)            40 (34, 45)               0.196
  T1‐mapping, ms                                    1072 (1030, 1116)      1082 (1052, 1122)         0.173
  Laboratory                                                                                         
  Hemoglobin, g/dL                                  13.4 (12.7, 14.6)      13.1 (11.9, 13.4)         0.084
  Anemia (WHO), n (%)                               6 (23.1)               10 (37.0)                 0.268
  TSAT, %                                           15.4 (9.6, 20.0)       15.7 (12.0, 19.2)         0.790
  Ferritin, ng/mL                                   47.8 (23.0, 114.0)     73.0 (56.0, 126.0)        0.072
  Absolute iron deficiency, n (%)                   19 (73.1)              18 (66.7)                 0.611
  Sodium, mEq/L                                     141 (140, 142)         140 (140, 142)            0.669
  Potassium, mEq/L                                  4.6 (4.4, 4.8)         4.7 (4.2, 5.0)            0.852
  Urea, mEq/L                                       59 (45, 84)            59 (45, 77)               0.669
  Serum creatinine, mg/dL                           1.1 (0.9, 1.5)         1.1 (0.9, 1.4)            0.783
  eGFR, mL/min per 1.73 m^2^                        64.1 (48.9, 79.3)      59.4 (50.0, 71.3)         0.854
  NT‐proBNP, pg/mL                                  1213 (1010, 2667)      1990 (976, 2830)          0.505
  Medical treatment                                                                                  
  Diuretics, n (%)                                  24 (92.3)              25 (92.6)                 0.969
  β‐blockers, n (%)                                 21 (80.8)              25 (92.6)                 0.204
  ACEI, n (%)                                       6 (23.1)               7 (25.9)                  0.810
  ARB, n (%)                                        4 (15.4)               5 (18.5)                  0.761
  Sacubitril/valsartan, n (%)                       8 (30.8)               10 (37.0)                 0.630
  Spironolactone, n (%)                             3 (11.5)               2 (7.4)                   0.607
  Eplerenone, n (%)                                 13 (50.0)              10 (37.0)                 0.341
  Digoxin, n (%)                                    4 (15.4)               1 (3.7)                   0.146
  Ibavradine, n (%)                                 1 (3.9)                4 (14.8)                  0.172
  Nitrates, n (%)                                   2 (7.7)                2 (7.4)                   0.969

WHO criteria for anemia: adult male, hemoglobin 13 g/dL; adult, nonpregnant female, hemoglobin 12 g/dL; adult pregnant female, hemoglobin 11 g/dL. Absolute iron deficiency: ferritin \<100 ng/mL. Values expressed as median (interquartile range); categorical variables are presented as percentages. ACEI indicates angiotensin‐converting enzyme inhibitors; AHF, acute heart failure; ARB, angiotensin II receptor blockers; bpm, beats per minute; CKD, chronic kidney disease; CMR, cardiac magnetic resonance; COPD, chronic pulmonary obstructive disease; eGFR, estimated glomerular filtration rate; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; LVEDDI, left ventricle end‐diastolic diameter index; LVEDVI, left ventricle end‐diastolic volume index; LVESDI, left ventricle end‐systolic diameter index; LVESVI, left ventricle end‐systolic volume index; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; TSAT, transferrin saturation; WHO, World Heart Organization.

Primary End Point {#jah34791-sec-0030}
-----------------

Compared with placebo, both 7‐day T2\* and T1 mapping were significantly lower in the FCM arm (36.6 ms \[34.6--38.7\] versus 40 ms \[38--42.1\], *P*=0.025; and 1061 ms \[1051--1072\] versus 1085 ms \[1074--1095\], *P*=0.001, respectively; Figure [2](#jah34791-fig-0002){ref-type="fig"}A). A similar reduction was found at 30 days for T2\* (36.3 ms \[34.1--38.5\] versus 41.1 ms \[38.9--43.4\], *P*=0.003), but this difference was no longer significant for T1 mapping (1075 ms \[1065--1085\] versus 1079 ms \[1069--1089\], *P*=0.577; Figure [2](#jah34791-fig-0002){ref-type="fig"}B).

![T2\* and T1 mapping after administration of FCM. **A**, Seven‐day comparison of LSM (95% CIs) between FCM and placebo. **B**, Thirty‐day comparison of LSM (95% CIs) between FCM and placebo. FCM indicates ferric carboxymaltose; LSM, least‐square means from a linear mixed regression analysis.](JAH3-9-e014254-g002){#jah34791-fig-0002}

Secondary End Points {#jah34791-sec-0031}
--------------------

1Relationship between CMR changes in T2\* and T1 mapping with concomitant changes in:a*LVEF:* LVEF did not significantly differ between both treatments at 7 or 30‐day (Table [2](#jah34791-tbl-0002){ref-type="table"}). In the FCM‐arm, a decrease in T2\* was significantly associated with an increase in LVEF (Figure [4](#jah34791-fig-0003){ref-type="fig"}A‐left). For T1‐mapping, the direction of the association was similar and significant (Figure [4](#jah34791-fig-0003){ref-type="fig"}A‐right).b*Quality of life:* At 30 days, higher values of KCCQ were observed in the FCM‐arm (76.9 \[73.6--80.1\] versus 70 \[66.8--73.3\], *P*\<0.001). However, there were no significant differences across treatment arms at 7‐day (Table [2](#jah34791-tbl-0002){ref-type="table"}). Furthermore, we found a significant association between the decrease in T1‐mapping with the increase in KCCQ in the FCM‐arm (Figure [4](#jah34791-fig-0003){ref-type="fig"}B‐right). The association between T2\* changes was not significant (Figure [4](#jah34791-fig-0003){ref-type="fig"}B‐left).c*Functional capacity:* We failed to find significant differences in 6MWT across both treatment strategies at both time points (Table [2](#jah34791-tbl-0002){ref-type="table"}). However, we find a significant association between reduction in T2\* and increase in 6MWT in the active arm (Figure [4](#jah34791-fig-0003){ref-type="fig"}C‐left). For ΔT1‐mapping, the association with Δ6MWT was not significant (Figure [4](#jah34791-fig-0003){ref-type="fig"}C‐right).d*NYHA class:* we found a significant lower value at 30 days in patients allocated to FCM (1.72 \[1.60--1.85\] versus 1.90 \[1.80--2.00\], *P*\<0.001). However, at 7‐day, the differences were not significant (Table [2](#jah34791-tbl-0002){ref-type="table"}). In the FCM‐arm, the greater improvement in NYHA class matched the reduction in T1‐mapping (Figure [4](#jah34791-fig-0003){ref-type="fig"}D‐right). However, this correlation was not significant for T2\* (Figure [4](#jah34791-fig-0003){ref-type="fig"}D‐left).e*Natriuretic peptides:* NT‐proBNP did not differ across treatment strategies at 7 or 30 days (Table [2](#jah34791-tbl-0002){ref-type="table"}). In the active arm, we found an inverse association between CMR changes and changes in NT‐proBNP (Figure [4](#jah34791-fig-0003){ref-type="fig"}E).2Relationship between CMR changes (T2\* and T1 mapping) and changes in iron biomarkers. Least‐square means values of ferritin and TSAT values were significantly higher in the FCM‐arm at 7 and 30 days as compared with placebo (Table [2](#jah34791-tbl-0002){ref-type="table"}). Furthermore, in the FCM arm, there was an inverse association between ΔT2\* (and ΔT1‐mapping) with Δ of surrogates of systemic iron repletion (Figure [3](#jah34791-fig-0004){ref-type="fig"}). Figure 3Association of posttreatment changes in myocardial iron content (T2\* and T1 mapping) with concomitant changes in systemic iron status in the active arm. **A**, Changes in CMR sequences and changes in ferritin; **B**,**A**, Changes in CMR sequences and changes in TSAT. Values are the least‐square means (95% CIs) from each linear regression analysis (OLS). TSAT indicates transferrin saturation.

###### 

Effect of Intervention on Surrogates of Severity and Iron Status Markers

  Variables          Placebo (n=26)      Intravenous Iron (n=27)   *P* Value
  ------------------ ------------------- ------------------------- -----------
  7‐d                                                              
  LVEF, %            42.6 (40.3--45)     42.5 (40.2--44.8)         0.916
  KCCQ               72.2 (66.8--77.6)   77.5 (72.5--82.5)         0.203
  6MWT, m            287 (269--304)      297 (280--313)            0.402
  NYHA class         1.91 (1.82--2.00)   1.90 (1.84--1.96)         0.700
  NT‐proBNP, pg/mL   1870 (1609--2131)   2305 (1859--2751)         0.102
  Ferritin, ng/mL    102 (71--132)       993 (908--1078)           \<0.001
  TSAT, %            16.1 (14.1--18.1)   41.3 (34.5--48.1)         \<0.001
  30‐d                                                             
  LVEF, %            40.9 (38.2--43.7)   44.8 (42.1--47.6)         0.056
  KCCQ               70 (66.8--73.3)     76.9 (73.6--80.1)         \<0.001
  6MWT, m            299 (266--332)      299 (279--320)            0.992
  NYHA class         1.90 (1.80--2.00)   1.72 (1.60--1.85)         \<0.001
  NT‐proBNP, pg/mL   2656 (1891--3421)   2366 (1741--2992)         0.675
  Ferritin, ng/mL    96 (68--124)        456 (434--479)            \<0.001
  TSAT, %            15 (14.1--15.8)     30.4 (26.1--34.8)         \<0.001

Values presented are the least‐square means (95% CIs) from each mixed linear regression model. All models were adjusted by hospital center (as a cluster variable), the interaction term Tx×visit (7 and 30‐day), baseline value of hemoglobin, and the baseline (pretreatment) value of the regressed outcome. 6MWT indicates distance walked in 6 minutes; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; TSAT, transferrin saturation.

![Association of posttreatment changes in myocardial iron content (T2\* and T1 mapping) with concomitant changes in surrogate markers of disease severity in the active‐arm. **A**, Changes in CMR sequences and changes in LVEF; **B**, Changes in CMR sequences and changes in KCCQ; **C**, Changes in CMR sequences and changes in 6MWT; **D**, Changes in CMR sequences and changes in NYHA class; **E**, Changes in CMR sequences and changes in NT‐proBNP. Values are the least‐square means (95% CIs) from each linear regression analysis (OLS). 6MWT indicates distance walked in 6 minutes; CMR, cardiac magnetic resonance; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.](JAH3-9-e014254-g003){#jah34791-fig-0003}

Discussion {#jah34791-sec-0032}
==========

For the first time in a clinical setting, we found that treatment with FCM resulted in significant and short‐term changes in CMR sequences that are consistent with myocardial iron repletion. Interestingly, these surrogates of myocardial iron repletion were, in most cases, related to systemic iron repletion and short‐term improvement in LVEF and other surrogates of severity such as 6MWT and quality of life. Our results are in line with prior studies showing the clinical utility of iron supplementation in HF‐ID patients, and more importantly, provide new insights into the role that myocardial iron repletion may play in these beneficial effects.

ID and Heart Failure {#jah34791-sec-0033}
--------------------

Iron is a micronutrient that plays a crucial role in oxygen transport and storage, and as a component of the mitochondrial respiratory chain is involved in energy production.[10](#jah34791-bib-0010){ref-type="ref"}, [11](#jah34791-bib-0011){ref-type="ref"}, [12](#jah34791-bib-0012){ref-type="ref"}, [13](#jah34791-bib-0013){ref-type="ref"}, [23](#jah34791-bib-0023){ref-type="ref"} In vitro studies have shown that cellular iron depletion in cardiomyocytes is associated with mitochondrial dysfunction, impaired ATP synthesis, increased oxidative stress in these cells, and that all these factors promote a profound impairment of systolic and diastolic properties of the cardiomyocytes.[12](#jah34791-bib-0012){ref-type="ref"} In the clinical context, ID is highly prevalent in patients with HF and commonly associated with adverse outcomes.[1](#jah34791-bib-0001){ref-type="ref"}, [2](#jah34791-bib-0002){ref-type="ref"}, [3](#jah34791-bib-0003){ref-type="ref"}, [4](#jah34791-bib-0004){ref-type="ref"} In these patients, treatment of ID with FCM improves symptoms, exercise capacity, and quality of life, and reduces the risk of readmission.[1](#jah34791-bib-0001){ref-type="ref"}, [5](#jah34791-bib-0005){ref-type="ref"}, [6](#jah34791-bib-0006){ref-type="ref"}, [7](#jah34791-bib-0007){ref-type="ref"}, [8](#jah34791-bib-0008){ref-type="ref"} However, the pathophysiological link between exogenous iron repletion and clinical improvement is not totally elucidated. A subanalysis of the FAIR‐HF (Ferrinject assessment in patients with iron deficiency and chronic heart failure) study and other studies showed that clinical improvement in response to intravenous iron administration occurs in patients with or without anemia, suggesting that the beneficial effect of iron administration is, at least in part, independent of the erythropoietic response.[24](#jah34791-bib-0024){ref-type="ref"}

Iron Supplementation and Myocardial Performance in HF Patients {#jah34791-sec-0034}
--------------------------------------------------------------

In the clinical setting, the evidence regarding the myocardial effect of iron supplementation is scarce. For example, in a small randomized trial with HF, ID, and chronic kidney disease, Toblli et al[25](#jah34791-bib-0025){ref-type="ref"} showed that iron sucrose administration translated into a significant 6‐month improvement in LVEF estimated by echocardiography (6.6 ± 3.8%). Other studies have also shown a significant reduction in the plasma level of NT‐proBNP and attenuation of hypertrophic cardiac remodeling.[26](#jah34791-bib-0026){ref-type="ref"}, [27](#jah34791-bib-0027){ref-type="ref"} The present study goes a step further in this regard and provides evidence that the improvement is related to benefits at the cardiac level with myocardial iron repletion that translates in improvements in cardiac function and patient functioning.

Quantification of Myocardial Iron Changes by CMR {#jah34791-sec-0035}
------------------------------------------------

CMR is an accurate and noninvasive technique that enables the characterization of cardiac structure, function, and risk stratification.[28](#jah34791-bib-0028){ref-type="ref"} This technique has been used to estimate myocardial iron content.[15](#jah34791-bib-0015){ref-type="ref"}, [16](#jah34791-bib-0016){ref-type="ref"} For example, lower T2\* CMR sequence values have been shown to provide a reliable assessment of myocardial iron overload.[15](#jah34791-bib-0015){ref-type="ref"}, [16](#jah34791-bib-0016){ref-type="ref"} More interestingly, changes in T2\* following chelation therapy are strongly related to the response to therapy in patients with iron overload.[29](#jah34791-bib-0029){ref-type="ref"} Regarding ID, in a small case--control study, Nagao et al[17](#jah34791-bib-0017){ref-type="ref"} suggested that cardiac T2\* may also play a role in the quantification of myocardial ID in nonischemic HF. In addition, these authors reported that T2\* CMR was related to an increased risk of adverse outcomes.[17](#jah34791-bib-0017){ref-type="ref"} Furthermore, new CMR techniques, such as T1 mapping, have been found to be a potential alternative tool for myocardial iron quantification.[18](#jah34791-bib-0018){ref-type="ref"} To the best of our knowledge, this is the first controlled clinical trial showing that treatment with FCM is associated with significant short‐term decreases in T1 mapping and T2\* CMR values, changes that are indicative of myocardial iron repletion. Indeed, we found a 7‐day decrease in both CMR sequences; however, at 30 days only T2\* was decreased. Interestingly, these changes were strongly related to a concomitant improvement in LVEF and other surrogates of disease severity. Unfortunately, our study was not designed to further evaluate this discrepancy among T2\* and T1 mapping at 30 days. Beyond the potential role of type II error, we speculate that changes in T1 mapping at later times may also reflect changes in other tissue characteristics. T1‐mapping values are influenced by several other conditions, such as fibrosis, inflammation/edema, amyloid, and Fabry disease.[18](#jah34791-bib-0018){ref-type="ref"} Despite the fact that all enrolled patients exhibited systemic ID, baseline T2\* values did not correlate with systemic markers of ID. This fact may reflect a lack of agreement between traditional markers of ID and myocardial tissue iron, as shown in previous publications[30](#jah34791-bib-0030){ref-type="ref"} or, perhaps, a lack of specificity of the baseline values of these CMR sequences for identifying myocardial ID in clinical practice. We do not believe the present findings have a direct translation into daily clinical practice. However, given the emerging role of iron biology in the pathophysiology of HF, we believe further research should test a clinical utility of the present findings or focus on the development of more specific and accurate noninvasive imaging techniques and better biomarkers for estimating myocardial iron content. This would translate into a better selection of HF patients who would most benefit from iron supplementation.

Limitations {#jah34791-sec-0036}
-----------

This trial has some limitations to be acknowledged. First, some negative results may be explained by insufficient statistical power. Second, CMR end points are well‐established imaging sequences for evaluating myocardial iron overload but not myocardial iron deficiency. In addition, their values and changes are not specific to myocardial iron content and may reflect the turnover of other tissue. Neither CMR sequence can discriminate whether tissue changes occur in an intra‐ or extracellular compartment. Third, as limited by the study design, we cannot prove any correlation between myocardial histological or myocardial energetic efficiency aspects with the administration of FCM. Performing a myocardial biopsy to conduct such studies would be considered ethically conflicting. Fourth, in the present study we did not evaluate the effect of iron treatment on skeletal muscle function, a potential mechanism that may also explain the beneficial effect of iron in HF patients. Fifth, in order to avoid interference with CMR sequences, patients with cardiac devices were excluded from this study. Sixth, the subgroup analysis was not reported given the small size of the study. Finally, despite the fact that the magnitude of changes we found in surrogates of the disease (LVEF, quality of life, functional capacity, and NYHA class) appears not to be clinically relevant, this study was not designed to quantify the effect of FCM nor magnitude of these changes.

Conclusions {#jah34791-sec-0037}
===========

In patients with stable HF and ID, administration of FCM led to a greater reduction in CMR T2\* and T1‐mapping values compared with placebo in the short‐term. Both changes are suggestive of myocardial iron repletion. Further studies are warranted to confirm these findings and to evaluate the potential utility of CMR for assessing myocardial iron content.

Appendix {#jah34791-sec-0038}
========

Myocardial Iron Study Group Investigators {#jah34791-sec-0039}
-----------------------------------------

*Cardiology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, INCLIVA, Valencia, Spain*: Julio Núñez, MD, PhD, Gema Miñana, MD, PhD, Ingrid Cardells, MD, Martina Amiguet, MD, Jessika González, MD, Ernesto Valero, MD, Sergio García‐Blas, MD, Vicent Bodí, MD, PhD, Rafael de la Espriella‐Juan, MD, Jorge Navarro, MD, PhD, Juan Sanchis, MD, PhD, Francisco J. Chorro, MD, PhD, Meritxell Soler, MD, Amparo Villaescusa, Jose Civera, Anna Mollar, PhD.

*Cardiology Department, Hospital General de Castellón. Universitat Jaume I, Castellón, Spain*: Patricia Palau, MD, PhD, Alicia Serrano, MD.

*Internal Medicine Department, Hospital de Manises, Manises, Spain*: Pau Llàcer, MD, PhD, Maria del Carmen Moreno, MD.

*Cardiology Department, Hospital General Universitario de Valencia, Valencia, Spain*: Lorenzo Fácila, MD, PhD, Vicente Montagud, MD, Veronica Vidal, MD.

*Cardiology Department, Hospital Universitario La Fe de Valencia, Valencia, Spain*: Luis Almenar, MD, PhD, Raquel López‐Vilella, MD.

*Unidad de Imagen Cardiaca (ERESA) Hospital Clínico Universitario de Valencia, Valencia, Spain:* Maria P. López‐Lereu, MD, PhD, Jose V. Monmeneu, MD, PhD.

*Cardiology Department and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Universitat Autonoma de Barcelona, Barcelona, Spain:* Antoni Bayés‐Genís, MD, PhD, Josep Lupón, MD, PhD.

*Nephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, INCLIVA, Valencia, Spain:* José Luis Górriz, MD, PhD.

*Department of Cardiology, Hospital del Mar, Barcelona, Spain Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Department of Medicine, Universitat Autònoma de Barcelona, Spain:* Josep Comín‐Colet, MD, PhD.
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[^1]: A complete list of the Myocardial‐IRON Investigators can be found in the Appendix at the end of the article.
